# Evaluate the Neurological Effects of EryDex on Subjects With A-T

> **NCT06193200** · PHASE3 · COMPLETED · sponsor: **Quince Therapeutics S.p.A.** · enrollment: 105 (actual)

## Conditions studied

- Ataxia Telangiectasia

## Interventions

- **DRUG:** Dexamethasone sodium phosphate
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06193200
- **Lead sponsor:** Quince Therapeutics S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-06-24
- **Primary completion:** 2025-12-17
- **Final completion:** 2025-12-17
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2026-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06193200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06193200, "Evaluate the Neurological Effects of EryDex on Subjects With A-T". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06193200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*